An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis.
BACKGROUND: Familial cylindromatosis is a rare genetic disorder, giving rise to neoplasms of the skin appendages. We have recently shown that loss of the cylindromatosis tumour suppressor gene leads to activation of NF-kappaB, a transcription factor having antiapoptotic activity. This provides a pos...
| Główni autorzy: | , , , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
2006
|
| _version_ | 1826278083862200320 |
|---|---|
| author | Oosterkamp, H Neering, H Nijman, S Dirac, A Mooi, W Bernards, R Brummelkamp, T |
| author_facet | Oosterkamp, H Neering, H Nijman, S Dirac, A Mooi, W Bernards, R Brummelkamp, T |
| author_sort | Oosterkamp, H |
| collection | OXFORD |
| description | BACKGROUND: Familial cylindromatosis is a rare genetic disorder, giving rise to neoplasms of the skin appendages. We have recently shown that loss of the cylindromatosis tumour suppressor gene leads to activation of NF-kappaB, a transcription factor having antiapoptotic activity. This provides a possible explanation for the deregulated growth of cylindromas. In cell-based assays, salicylate can prevent NF-kappaB activation caused by loss of the cylindromatosis gene, suggesting that salicylic acid application might be a potential treatment for cylindromatosis. OBJECTIVES: To assess the effectiveness of topical application of salicylic acid on familial cylindromas. METHODS: Cylindromas in five patients from four different cylindromatosis families were treated with twice daily and then once daily topical salicylic acid. Clinical response was determined by serial tumour measurements. RESULTS: In total 17 cylindromas in five patients were studied: 12 target lesions and five control lesions. The median size of the cylindromas was 1.0 cm (range, 0.6-2.8 cm). Two of the 12 cylindromas showed a complete remission. Another eight lesions showed some response, but not sufficient to qualify as partial remission. The control lesions remained stable or increased in size. CONCLUSIONS: Salicylic acid is a well-tolerated and potential new treatment for cylindromatosis. |
| first_indexed | 2024-03-06T23:38:39Z |
| format | Journal article |
| id | oxford-uuid:6e869066-82bc-4d4c-9bfc-3f2999b2f741 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:38:39Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:6e869066-82bc-4d4c-9bfc-3f2999b2f7412022-03-26T19:25:05ZAn evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6e869066-82bc-4d4c-9bfc-3f2999b2f741EnglishSymplectic Elements at Oxford2006Oosterkamp, HNeering, HNijman, SDirac, AMooi, WBernards, RBrummelkamp, TBACKGROUND: Familial cylindromatosis is a rare genetic disorder, giving rise to neoplasms of the skin appendages. We have recently shown that loss of the cylindromatosis tumour suppressor gene leads to activation of NF-kappaB, a transcription factor having antiapoptotic activity. This provides a possible explanation for the deregulated growth of cylindromas. In cell-based assays, salicylate can prevent NF-kappaB activation caused by loss of the cylindromatosis gene, suggesting that salicylic acid application might be a potential treatment for cylindromatosis. OBJECTIVES: To assess the effectiveness of topical application of salicylic acid on familial cylindromas. METHODS: Cylindromas in five patients from four different cylindromatosis families were treated with twice daily and then once daily topical salicylic acid. Clinical response was determined by serial tumour measurements. RESULTS: In total 17 cylindromas in five patients were studied: 12 target lesions and five control lesions. The median size of the cylindromas was 1.0 cm (range, 0.6-2.8 cm). Two of the 12 cylindromas showed a complete remission. Another eight lesions showed some response, but not sufficient to qualify as partial remission. The control lesions remained stable or increased in size. CONCLUSIONS: Salicylic acid is a well-tolerated and potential new treatment for cylindromatosis. |
| spellingShingle | Oosterkamp, H Neering, H Nijman, S Dirac, A Mooi, W Bernards, R Brummelkamp, T An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. |
| title | An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. |
| title_full | An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. |
| title_fullStr | An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. |
| title_full_unstemmed | An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. |
| title_short | An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. |
| title_sort | evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis |
| work_keys_str_mv | AT oosterkamph anevaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT neeringh anevaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT nijmans anevaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT diraca anevaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT mooiw anevaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT bernardsr anevaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT brummelkampt anevaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT oosterkamph evaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT neeringh evaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT nijmans evaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT diraca evaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT mooiw evaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT bernardsr evaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis AT brummelkampt evaluationoftheefficacyoftopicalapplicationofsalicylicacidforthetreatmentoffamilialcylindromatosis |